TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases... Show more
TGTX moved above its 50-day moving average on March 03, 2025 date and that indicates a change from a downward trend to an upward trend. In of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on March 03, 2025. You may want to consider a long position or call options on TGTX as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The 10-day moving average for TGTX crossed bullishly above the 50-day moving average on March 05, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where TGTX advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for TGTX moved out of overbought territory on March 26, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 59 cases where TGTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for TGTX turned negative on March 27, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TGTX broke above its upper Bollinger Band on March 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TGTX entered a downward trend on February 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.409) is normal, around the industry mean (14.047). P/E Ratio (268.000) is within average values for comparable stocks, (66.086). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.907). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (19.608) is also within normal values, averaging (239.969).
a biopharmaceutical company
Industry Biotechnology
A.I.dvisor indicates that over the last year, TGTX has been loosely correlated with VANI. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if TGTX jumps, then VANI could also see price increases.
Ticker / NAME | Correlation To TGTX | 1D Price Change % | ||
---|---|---|---|---|
TGTX | 100% | -1.45% | ||
VANI - TGTX | 39% Loosely correlated | +2.68% | ||
ALT - TGTX | 38% Loosely correlated | -0.36% | ||
ARRY - TGTX | 36% Loosely correlated | -2.29% | ||
CLLS - TGTX | 36% Loosely correlated | N/A | ||
AXON - TGTX | 36% Loosely correlated | -1.50% | ||
More |